Nearly half of PBC patients in US haven’t seen a specialist recently
About 40 in every 100,000 U.S. adults have primary biliary cholangitis (PBC), with its frequency, when adjusted to population size, being highest in some…
Margarida Maia, PhD, Science Writer—
Articles by Margarida Maia
Researchers develop mutation database, mouse model for PFIC2
Researchers have developed a database of all ABCB11 mutations known to cause progressive familial intrahepatic cholestasis type 2 (PFIC2) and a new mouse model…
Targeted chemotherapy effective for HCC in woman with Alagille
A targeted treatment called transarterial chemoembolization (TACE) successfully helped control hepatocellular carcinoma (HCC), the most common type of liver cancer, in a young woman with…
AusperBio raises $50M to advance AHB-137 for chronic hepatitis B
AusperBio raised $50 million to advance the development of chronic hepatitis B treatment AHB-137. The company said the funding will help it launch Phase…
FDA to review linerixibat for PBC-related itching
The U.S. Food and Drug Administration (FDA) has accepted for review GSK’s application seeking the approval of its oral treatment linerixibat for intense itching, or…
Vaccination, testing encouraged as part of Hepatitis Awareness Month
Hepatitis Awareness Month is held every May to raise awareness about viral hepatitis, an inflammation of the liver caused by a virus, and help…
Air pollution may raise intrahepatic cholestasis of pregnancy risk
Exposure to high levels of fine particulate matter, or PM2.5, the most commonly studied air pollutant, and reduced time in the sunlight in the three…
New PFIC3-causing mutations identified in 3 children in China
A study of three children with progressive familial intrahepatic cholestasis type 3 (PFIC3) in China revealed that different disease-causing mutations in the ABCB4 gene,…
Bile acid levels may predict outcome of Kasai surgery for biliary atresia
Measuring the blood levels of bile acids, the main component of the digestive fluid bile, can help predict key clinical outcomes for babies with…
2nd-line PBC treatment options call for personalized care: Analysis
Among second-line treatments for primary biliary cholangitis (PBC), Iqirvo (elafibranor) may work better than Livdelzi (seladelpar) at reducing markers of liver damage, while Livdelzi…
